Observational studyThe journal of headache and pain2021

Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study).

Fabrizio Vernieri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.